PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. - Wikidata - awgldk - TriplyDB

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

http://www.wikidata.org/entity/Q32033296

about

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis PPARs and the cardiovascular system The peroxisome proliferator activated receptor delta is required for the differentiation of THP-1 monocytic cells by phorbol ester Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation.Inflammation, obesity, and thrombosis Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review Emerging therapeutic targets of sepsis-associated acute kidney injury.The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective.Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages Activated Monocytes Enhance Platelet-Driven Contraction of Blood Clots via Tissue Factor Expression L-carnitine protects against carboplatin-mediated renal injury: AMPK- and PPARα-dependent inactivation of NFAT3.The Role of PPARα Activation in Liver and Muscle.Stabilization of atherosclerotic plaques: new mechanisms and clinical targets.PPAR-alpha effects on the heart and other vascular tissues.Tissue factor, blood coagulation, and beyond: an overview.Peroxisome proliferator-activated receptor ligands in atherosclerosis.Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications.PPARalpha in atherosclerosis and inflammation.Pleiotropic effects of fibrates.Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.Recent findings concerning thiazolidinediones in the treatment of diabetes.Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.PPARs and molecular mechanisms of transrepression Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system Modulation of endothelial cell thrombomodulin by PPAR ligands--variation according to environment.Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?Nuclear receptors and inflammatory diseases.Molecular mechanisms involved in NAFLD progression.Influence of conjugated linoleic acids on functional properties of vascular cells.HDL inflammation and atherosclerosis: current and future perspectives.Peroxisome proliferator-activated receptors and atherosclerosis.Therapeutic Potential of PPARγ Activation in Stroke.The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.PPARα as a therapeutic target in inflammation-associated diseases.Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists

P2860

Q24541529-6E474533-AEB1-4B54-97D6-59F7130131A9 Q24642728-AE15B561-8AA1-407D-AF8B-BAEC1A1F2312 Q24806798-83138E6C-5039-45DE-90F8-44F1340BBF6F Q24806958-AEC38F43-C761-4926-96CE-811851E090CD Q27008937-889CF884-DFA5-49BC-81F7-F5E44B8A7303 Q28220294-FFB1A02C-6915-40FB-AE80-E05C52711D1B Q30300333-51802743-A3B7-4FB7-BAED-C34B4F8A323A Q30357715-9B58918B-F911-4399-AB96-B145F49F44C8 Q33306319-BE45B5B5-BD1E-479C-869E-FA16D7036773 Q33870766-09BD2643-4F82-43BE-AFC4-2DD8363A2F4E Q33894973-C9FCD3D5-F7D4-46A9-8345-C3665F79FD16 Q34000195-58DC0DB6-7340-4FCA-BF66-2F821FE5006F Q34106233-CE8D7BC4-69AE-46C3-8E2C-201C00DF6DB9 Q34986368-638BCA74-AD52-4234-8027-9DF3CAB6D4F5 Q35080447-1FBDE930-803B-4B0F-BD46-FBD1CBCEBF26 Q35222618-A493C225-93DA-4B4A-9708-1502AA423EB1 Q35925566-27230C86-A8B4-4A44-BA16-BBFA46298A4B Q35940672-FF1E501A-08D4-4959-AEFD-D5DCF4A6A020 Q36154953-528818D7-7B81-4D38-8CCA-03A0F111A784 Q36232396-6BB931F7-5546-4FCF-99CC-EB076C28CE97 Q36401585-C870DA11-ADF4-49C5-8438-C7B9FA129FB0 Q36407304-015DA5FF-13B7-4FEB-AFDD-A15ECB9261A0 Q36438737-38476AB5-DE1B-4586-9DC7-0A8DC54880B8 Q36580568-C69784DB-C676-4488-9DC4-E50A7F1E3C7D Q36791361-EC6712B6-9D5D-416A-B128-A6597CF32BC6 Q36894180-AD58A7D6-E261-4D65-BB46-9F516565ABB0 Q36952106-5C2DF890-2713-4473-8007-1390119A86B8 Q36960958-3DE5A90F-5BB2-43F9-935D-B17779CD09F2 Q36992256-A14FC877-20C3-4479-B5A9-61259CDDABA6 Q37016305-0CD70FBD-E654-4112-BD1E-DF874949F091 Q37119252-946DA0F1-7BB2-47B8-8617-78217D1CDF6E Q37122891-6B664F3B-A1B8-440B-8DD1-08C49B660D1C Q37437295-534D8311-8D4E-44CE-BB1B-FC56C336F06A Q37557746-C32190CE-3DD3-4FA7-9EB2-E9B40C14C8C5 Q37608502-B314E5F2-3C4A-43DE-AEC5-4786B795B5B0 Q37861955-15417E64-71DD-4477-B300-BE1559AA44ED Q37930425-42E162A9-D39C-4C72-A574-AC7912FB7EAC Q37997004-350D7202-CF73-4DF4-8F53-E0C5E86F7826 Q38038289-C8438F07-41B0-40AC-8E77-9D3F5D0A4938 Q38110581-711D50A8-DBE2-4879-A2A6-53485968FD4A

P2860

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

http://www.wikidata.org/entity/Q32033296

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

@ast

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

@en

type

label

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

@ast

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

@en

prefLabel

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

@ast

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

@en

P1433

Q32033296-4370B64F-DD16-441C-8DA3-9FDD9D54E305

P1476

Q32033296-A2BCC51B-FDF6-4097-A9A2-0705767D1C2F

P2093

Q32033296-16BBA555-4A5B-4327-932E-6451971D54B9

Q32033296-3AAA5D9B-57AC-43C2-876B-485ADC31722C

Q32033296-4B5FF53A-C4FB-4E39-84B6-C932C217F0D7

Q32033296-53C64072-E358-4C54-8009-73DC15FEFD5A

Q32033296-5F95DEC3-CE63-451E-ABF6-3050F06255C5

Q32033296-7802D896-8DDE-4DA5-8C29-51D2B9422AC3

Q32033296-7B8D690B-83A7-4351-AB73-4E1951D69AB0

Q32033296-A2986CD3-F365-4B70-BF1F-0182EB5CBEB5

P304

Q32033296-CD3419DE-343D-427F-A40D-85FB55767F70

P31

Q32033296-3D58D0DF-829F-473F-9BFA-81DCC6FB1440

P356

Q32033296-748401D9-2790-4189-869F-82E4165E8D9E

P407

Q32033296-0DAEC401-DE2E-43FE-BAA7-79891682E074

P433

Q32033296-2E828494-92DA-4478-B66D-DE7A962AA069

P478

Q32033296-BDE5682A-29C1-426F-8FF0-6F2991A0787B

P577

Q32033296-0640BDF8-376A-4C97-BE62-6EAD09AB8DC4

P698

Q32033296-DFC4313C-C73E-4C18-A6E1-60BE2CB2362A

P356

01.CIR.103.2.207

P1433

P1476

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

@en

P2093

Chinetti G

http://www.w3.org/2001/XMLSchema#string

Corseaux D

http://www.w3.org/2001/XMLSchema#string

Duriez P

http://www.w3.org/2001/XMLSchema#string

Fruchart JC

http://www.w3.org/2001/XMLSchema#string

Jude B

http://www.w3.org/2001/XMLSchema#string

Neve BP

http://www.w3.org/2001/XMLSchema#string

Staels B

http://www.w3.org/2001/XMLSchema#string

Zawadzki C

http://www.w3.org/2001/XMLSchema#string

P304

207-212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.103.2.207

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2001-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11208678

http://www.w3.org/2001/XMLSchema#string